Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
ACS Medicinal Chemistry Letters|June 22, 2019
Discovery of SHR1653, a Highly Potent and Selective OTR Antagonist with Improved Blood-Brain Barrier PenetrationXin Li, Zhigao Zhang, Yang Chen, et al.
Endocrinology|September 17, 2005
A novel and selective beta-melanocyte-stimulating hormone-derived peptide agonist for melanocortin 4 receptor potently decreased food intake and body weight gain in diet-induced obese ratsHansen M Hsiung, Jeanne Hertel, Xing-Yue Zhang, et al.
Peptides|March 3, 2007
pI-shifted insulin analogs with extended in vivo time action and favorable receptor selectivityWayne D Kohn, Radmila Micanovic, Sharon L Myers, et al.
Research and Practice in Thrombosis and Haemostasis|March 20, 2023
BJTJ-1837, a novel FXI activation-blocking antibodyXugang He, Jin Zhang, Yanping Du, et al.
ACS Medicinal Chemistry Letters|February 20, 2018
Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin's LymphomaBiao Lu, Xiaodong Shen, Lei Zhang, et al.
Bioorganic & Medicinal Chemistry Letters|January 8, 2016
Discovery of EBI-907: A highly potent and orally active B-Raf(V600E) inhibitor for the treatment of melanoma and associated cancersBiao Lu, Hu Cao, Jingsong Cao, et al.
Oncotargets and Therapy|September 1, 2021
A Novel CD73 Inhibitor SHR170008 Suppresses Adenosine in Tumor and Enhances Anti-Tumor Activity with PD-1 Blockade in a Mouse Model of Breast CancerSuxing Liu, Di Li, Jian Liu, et al.
Cancer Biology & Therapy|January 27, 2016
EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profileJiayin Zhang, Biao Lu, Dong Liu, et al.
ACS Medicinal Chemistry Letters|February 19, 2021
Discovery of Hydroxyamidine Derivatives as Highly Potent, Selective Indoleamine-2,3-dioxygenase 1 InhibitorsFangfang Jin, Qiyue Hu, Hongbo Fei, et al.
Current Topics in Medicinal Chemistry|June 23, 2007
Structure-activity relationships of beta-MSH derived melanocortin-4 receptor peptide agonistsLiang Zeng Yan, Hansen M Hsiung, Mark L Heiman, et al.
Pageof 8